Miliary tuberculosis

New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World

Retrieved on:

Monday, March 25, 2024

MANILA, Australia, March 24, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding from the Australian Government through the Partnerships for a Healthy Region initiative. PeerLINC, operating in partnership between TB Alliance and the Tropical Disease Foundation, Inc. (TDF), and in close collaboration with the Department of Health, Philippines, will help countries implement best practices in the treatment of drug-resistant tuberculosis (DR-TB) to help speed the worldwide programmatic implementation of innovative, more effective treatments for the disease, starting with the World Health Organization (WHO)-recommended six-month, all-oral BPaL/M regimens, composed of the antibiotics bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without moxifloxacin (M).

Key Points:

The Philippines has successfully and rapidly deployed new treatments through participation in TB Alliance's Leveraging Innovation for Faster TB Treatment ( LIFT-TB ) initiative.
"PeerLINC will make training and knowledge on new treatments available swiftly and efficiently to ensure their rapid adoption and roll out.
"Every country with drug-resistant TB can benefit from widespread implementation of the best available TB treatment.
The expert team from PeerLINC will continue to guide countries after trainings, as they work to implement the regimens.

New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World

Retrieved on:

Monday, March 25, 2024

MANILA, Australia, March 25, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding from the Australian Government through the Partnerships for a Healthy Region initiative. PeerLINC, operating in partnership between TB Alliance and the Tropical Disease Foundation, Inc. (TDF), and in close collaboration with the Department of Health, Philippines, will help countries implement best practices in the treatment of drug-resistant tuberculosis (DR-TB) to help speed the worldwide programmatic implementation of innovative, more effective treatments for the disease, starting with the World Health Organization (WHO)-recommended six-month, all-oral BPaL/M regimens, composed of the antibiotics bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without moxifloxacin (M).

Key Points:

The Philippines has successfully and rapidly deployed new treatments through participation in TB Alliance's Leveraging Innovation for Faster TB Treatment ( LIFT-TB ) initiative.
"PeerLINC will make training and knowledge on new treatments available swiftly and efficiently to ensure their rapid adoption and roll out.
"Every country with drug-resistant TB can benefit from widespread implementation of the best available TB treatment.
The expert team from PeerLINC will continue to guide countries after trainings, as they work to implement the regimens.

Cancer therapy shows promise against tuberculosis

Retrieved on:

Thursday, November 16, 2023

SAN ANTONIO, Nov. 16, 2023 /PRNewswire/ -- A promising new cancer therapy also appears extremely potent against one of the world's most devastating infectious diseases: tuberculosis (TB).

Key Points:

SAN ANTONIO, Nov. 16, 2023 /PRNewswire/ -- A promising new cancer therapy also appears extremely potent against one of the world's most devastating infectious diseases: tuberculosis (TB).
- Larry Schlesinger, MD
Scientists at Texas Biomedical Research Institute (Texas Biomed) found the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant.
The therapy evaluated in this study combines two molecules – one is already FDA-approved for cancer patients, and the other is in Phase 1/2 clinical trials for cancer.
That's the power of a host-directed therapy targeting the human's immune response versus trying to attack the pathogen directly."

TB Alliance Applauds Macleods' Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen

Retrieved on:

Monday, November 13, 2023

World Health Organization, Medicine, Tuberculosis, Senior, Miliary tuberculosis, WHO, Patient, Infection, Pretomanid, Stop TB Partnership, Moxifloxacin, Dauntless (video game), Linezolid, Market access, TB Alliance, TB, Pharmaceutical industry, Colin Munro MacLeod

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Indian pharmaceutical company Macleods has become the second manufacturer to launch pretomanid, a new medicine and essential component of shortened, World Health Organization (WHO)-recommended treatment regimens for drug-resistant tuberculosis (DR-TB). Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries. Macleods has recently commenced supplying pretomanid to the Stop TB Partnership's Global Drug Facility for distribution of the medicine to those countries.

Key Points:

Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries.
Pretomanid was developed by the nonprofit TB Alliance, as part of the all-oral, six-month BPaL (bedaquiline + pretomanid + linezolid) regimen used with or without moxifloxacin (BPaL/M).
Previously, drug-resistant TB treatment lasted 9 to 18 months or longer and often required people to take up to 14,000 pills over the course of treatment.
BPaL is the first set treatment regimen recommended to treat drug-resistant TB.

TB Alliance Applauds Macleods' Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen

Retrieved on:

Monday, November 13, 2023

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Indian pharmaceutical company Macleods has become the second manufacturer to launch pretomanid, a new medicine and essential component of shortened, World Health Organization (WHO)-recommended treatment regimens for drug-resistant tuberculosis (DR-TB). Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries. Macleods has recently commenced supplying pretomanid to the Stop TB Partnership's Global Drug Facility for distribution of the medicine to those countries.

Key Points:

Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries.
Pretomanid was developed by the nonprofit TB Alliance, as part of the all-oral, six-month BPaL (bedaquiline + pretomanid + linezolid) regimen used with or without moxifloxacin (BPaL/M).
Previously, drug-resistant TB treatment lasted 9 to 18 months or longer and often required people to take up to 14,000 pills over the course of treatment.
BPaL is the first set treatment regimen recommended to treat drug-resistant TB.

Kyrgyzstan, Ukraine, and Uzbekistan Update National Guidelines for Drug-Resistant TB Treatment to Advance National Rollout of Three-Drug, Six-Month Regimen

Retrieved on:

Monday, September 18, 2023

PRETORIA, South Africa, Sept. 18, 2023 /PRNewswire/ -- Kyrgyzstan, Ukraine, and Uzbekistan — participants in the LIFT-TB project — have updated their National Tuberculosis (TB) Clinical Guidelines to endorse the all-oral, six-month BPaL/M (bedaquiline + pretomanid + linezolid ± Moxifloxacin) regimen(s) as the national standard for treating most patients with drug-resistant tuberculosis (DR-TB).

Key Points:

Launched in 2020 , LIFT-TB is a program intended to broaden adoption and scale-up of innovative TB cures.
As part of LIFT-TB, Kyrgyzstan, Ukraine and Uzbekistan each completed operational research of the BPaL regimen.
They have also all committed to scaling up use of the treatment for drug-resistant TB.
"It is heartening to see countries participating in LIFT-TB emerge as leaders in scaling up access to new DR-TB treatments.

Kyrgyzstan, Ukraine, and Uzbekistan Update National Guidelines for Drug-Resistant TB Treatment to Advance National Rollout of Three-Drug, Six-Month Regimen

Retrieved on:

Monday, September 18, 2023

PRETORIA, South Africa, Sept. 18, 2023 /PRNewswire/ -- Kyrgyzstan, Ukraine, and Uzbekistan — participants in the LIFT-TB project — have updated their National Tuberculosis (TB) Clinical Guidelines to endorse the all-oral, six-month BPaL/M (bedaquiline + pretomanid + linezolid ± Moxifloxacin) regimen(s) as the national standard for treating most patients with drug-resistant tuberculosis (DR-TB).

Key Points:

Launched in 2020 , LIFT-TB is a program intended to broaden adoption and scale-up of innovative TB cures.
As part of LIFT-TB, Kyrgyzstan, Ukraine and Uzbekistan each completed operational research of the BPaL regimen.
They have also all committed to scaling up use of the treatment for drug-resistant TB.
"It is heartening to see countries participating in LIFT-TB emerge as leaders in scaling up access to new DR-TB treatments.

TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan

Retrieved on:

Monday, August 14, 2023

PVT, Partnership, TB Alliance, Public, TB, Linezolid, Miliary tuberculosis, Ministry of National Health Services, Regulation and Coordination, Medicine, Dauntless (video game), Government, Patient, Tuberculosis, Remington, WHO, Moxifloxacin, World Health Organization, Disease, Pharmaceutical industry

NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medicine pretomanid as part of the all-oral, six-month BPaL and BPaLM regimens for treatment of drug-resistant TB (comprised of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin). Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB. Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.

Key Points:

Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB.
Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.
"Remington is proud and thrilled to collaborate with TB Alliance to provide solutions that could change the lives of drug-resistant TB patients in Pakistan.
The partnership with Remington is part of TB Alliance's global commercialization strategy for pretomanid as part of the BPaL/BPaLM regimens.

TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan

Retrieved on:

Monday, August 14, 2023

NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medicine pretomanid as part of the all-oral, six-month BPaL and BPaLM regimens for treatment of drug-resistant TB (comprised of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin). Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB. Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.

Key Points:

Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB.
Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.
"Remington is proud and thrilled to collaborate with TB Alliance to provide solutions that could change the lives of drug-resistant TB patients in Pakistan.
The partnership with Remington is part of TB Alliance's global commercialization strategy for pretomanid as part of the BPaL/BPaLM regimens.

Emergence of Multidrug-Resistant Strains Steers Global Tuberculosis Therapeutics Market Towards $2.99 Billion by 2030 - ResearchAndMarkets.com

Retrieved on:

Thursday, July 20, 2023

The global tuberculosis therapeutics market size is expected to reach USD 2.99 billion, expanding at a CAGR of 5.09% from 2023 to 2030.

Key Points:

The global tuberculosis therapeutics market size is expected to reach USD 2.99 billion, expanding at a CAGR of 5.09% from 2023 to 2030.
The demand for TB therapeutics is attributable to the rising prevalence of tuberculosis.
The burden of drug-resistant tuberculosis (DR-TB) increased by 3% between 2020 and 2021, with 450 000 new cases of rifampicin-resistant tuberculosis in 2021.
Furthermore, key players are focusing on collaborations and partnerships to develop novel tuberculosis therapeutics and to maintain their competitive position in the market.